Clinical trial
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer…
NCT00409188 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00409188 |
|---|---|
| Title | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) |
| Official title | A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease. |
| Acronym | START |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo |
| Enrollment | 1,513 |
| Start date | Jan 1, 2007 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2015 |
| First posted | Dec 8, 2006 |
| Last update posted | Nov 20, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: